Equities
  • Price (EUR)12.00
  • Today's Change0.300 / 2.56%
  • Shares traded3.00
  • 1 Year change-9.77%
  • Beta0.3368
Data delayed at least 15 minutes, as of Feb 06 2026 15:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

  • Revenue in USD (TTM)3.83bn
  • Net income in USD626.55m
  • Incorporated1984
  • Employees27.81k
  • Location
    Dr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500-034IndiaIND
  • Phone+91 4 049002900
  • Fax+91 4 049002999
  • Websitehttps://www.drreddys.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DRREDDY:NSI since
announced
Transaction
value
Janssen Pharmaceutica Nv- Stugeron PortfolioDeal completed10 Sep 202510 Sep 2025Deal completed-4.11%50.39m
Data delayed at least 15 minutes, as of Feb 06 2026 10:26 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.